⌘K
t
| TIDM | CIZ |
| Share Price | Loading... |
| Market Cap | Loading... |
On June 28, 2023, Cizzle Biotechnology Holdings Plc announced that all resolutions were passed at the Company's Annual General Meeting. Proxy votes for each resolution, including the re-appointment of Allan John Syms as a Director and the re-appointment of PKF Littlejohn LLP as auditor, ranged from 95.92% to 97.11% in favor. Votes against each resolution ranged from 2.89% to 4.08%.
| Date | 28 Jun 2023 |
| Time | 12:01:18 |
| Category | AGMs and other meetings |
| ID | 2600E |
28 June 2023
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Result of AGM
Cizzle Biotechnology, the UK-based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a show of hands and were passed.
The proxy votes cast in respect of the resolutions were as follows:
|
Resolution |
For |
Against |
Votes withheld |
||
|
Total votes |
% |
Total votes |
% |
|
|
|
1. To receive the Company's annual report and accounts for the year ended 31 December 2022 |
89,757,080 |
97.11 |
2,672,935 |
2.89 |
1,661,693 |
|
2. To approve the Directors' Remuneration Report |
88,827,568
|
96.10 |
3,602,447 |
3.90 |
1,661,693 |
|
3. To re-appoint Allan John Syms as a Director of the Company |
88,827,578
|
96.14 |
3,568,237
|
3.86 |
1,695,893 |
|
4. To re-appoint PKF Littlejohn LLP as auditor of the Company |
88,861,778 |
96.14 |
3,568,237 |
3.86 |
1,661,693
|
|
5. To authorise the Directors to determine the auditor's remuneration |
88,861,778 |
96.14 |
3,568,237 |
3.86 |
1,661,693
|
|
6. Authorises the Directors to allot shares in the Company or to grant rights to subscribe for, or to convert any security into, shares in the Company |
88,661,778 |
95.92 |
3,768,237 |
4.08 |
1,661,693 |
|
7. Authorise the Directors to allot equity securities disapplying pre-emption rights |
88,823,568 |
96.10 |
3,606,437 |
3.90 |
1,661,703 |
|
8. That General Meetings may be called on not less than 14 days' notice |
88,861,778 |
96.14 |
3,568,237 |
3.86 |
1,661,693 |
Enquiries:
|
Cizzle Biotechnology Holdings plc |
Via IFC Advisory |
|
Allan Syms (Executive Chairman) |
|
|
Allenby Capital Limited |
+44(0) 20 33285656 |
|
John Depasquale |
|
|
Alex Brearley |
|
|
Novum Securities Limited |
+44(0) 20 7399 9400 |
|
Colin Rowbury Jon Bellis |
|
|
IFC Advisory Limited |
+44(0) 20 3934 6630 |
|
Tim Metcalfe |
cizzle@investor-focus.co.uk |
|
Florence Chandler |
|
Notes to Editors:
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.